公开(公告)号：EP0831925A1

公开(公告)日：1998-04-01

申请号：EP96917935.0

申请日：1996-06-03

申请人： WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH ,  THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

发明人： DRANOFF, Glenn ,  MULLIGAN, Richard C. ,  PARDOLL, Drew

IPC分类号： C12N15 ,  A61K38 ,  A61K39 ,  A61K48 ,  A61P35 ,  A61P37 ,  A61P43 ,  C07K14 ,  C12N5

CPC分类号： A61K39/21 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/57 ,  C07K14/52 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5406 ,  C07K14/5409 ,  C07K14/5412 ,  C07K14/545 ,  C07K14/55 ,  C07K14/57 ,  C07K14/705 ,  C07K14/70507 ,  C07K14/70525 ,  C12N15/85 ,  C12N2740/13034 ,  C12N2799/027 ,  C12N2840/44

摘要： A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine, an adhesion or accessory molecule, and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.

公开(公告)号：EP0607309B1

公开(公告)日：2003-01-08

申请号：EP92921896.4

申请日：1992-10-05

申请人： WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH ,  THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

发明人： DRANOFF, Glenn ,  MULLIGAN, Richard C. ,  PARDOLL, Drew

IPC分类号： A61K48/00 ,  A61K39/00 ,  A61P37/02 ,  C12N5/10

CPC分类号： C12N15/85 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K2039/55522 ,  C07K14/52 ,  C12N2740/16034

摘要： A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enchanted systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.

公开(公告)号：EP0607309A1

公开(公告)日：1994-07-27

申请号：EP92921896.0

申请日：1992-10-05

申请人： WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH ,  THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

发明人： DRANOFF, Glenn ,  MULLIGAN, Richard C. ,  PARDOLL, Drew

IPC分类号： C12N15 ,  A61K35 ,  A61K38 ,  A61K39 ,  A61P35 ,  A61P37 ,  C07K14 ,  C12N5 ,  C12P21 ,  A61K48 ,  C12R1

CPC分类号： C12N15/85 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K2039/55522 ,  C07K14/52 ,  C12N2740/16034

摘要： A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enchanted systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.

公开(公告)号：EP0763122A1

公开(公告)日：1997-03-19

申请号：EP95921253.0

申请日：1995-05-16

申请人： SOMATIX THERAPY CORPORATION ,  WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

发明人： RIVIERE, Isabelle ,  COHEN, Lawrence K. ,  GUILD, Brad ,  RAFIELD, Lori F. ,  ROBBINS, Paul ,  MULLIGAN, Richard C.

IPC分类号： C12N15 ,  A61K35 ,  A61K38 ,  A61K48 ,  A61L27 ,  A61L33 ,  A61P7 ,  C07K14 ,  C12N5 ,  C12N9

CPC分类号： A61L27/3821 ,  A61K35/28 ,  A61K38/00 ,  A61K48/00 ,  A61L27/3808 ,  A61L27/3839 ,  A61L27/507 ,  A61L33/18 ,  C07K14/635 ,  C07K14/705 ,  C07K14/755 ,  C12N5/069 ,  C12N9/2471 ,  C12N9/6459 ,  C12N9/78 ,  C12N15/86 ,  C12N2740/13043 ,  C12Y302/01023 ,  C12Y304/21069

摘要： Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

公开(公告)号：EP0833893A1

公开(公告)日：1998-04-08

申请号：EP96919187.0

申请日：1996-06-05

申请人： WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY

发明人： GOODELL, Margaret A. ,  CONNER, A.Stewart ,  MULLIGAN, Richard C.

IPC分类号： A61K35 ,  C12N5 ,  A61K38

CPC分类号： A61K35/28 ,  A61K38/00 ,  C12N5/0647

摘要： The present invention relates to a method of purifying mammalian hematopoietic stem cells from a bone marrow cell population. The present invention also relates to a method of separating cycling HSCs from quiescent HSCs in a purified mammalian HSC sample. Further, the invention relates to a method of identifying an agent which is a fluorescent, vital dye which is lipophilic for use in purifying mammalian HSCs. The present invention also relates to a method of transplanting bone marrow in a mammalian host, such as a human, comprising introducing into the host the purified HSCs described herein. The invention further relates to a method of in vivo administration of a protein comprising transfecting a purified HSC with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein of interest is expressed. The present invention also relates to hematopoietic stem cells purified using the methods described herein.